

# Sara I Pai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5430833/publications.pdf>

Version: 2024-02-01

138  
papers

9,135  
citations

76196

40  
h-index

40881

93  
g-index

140  
all docs

140  
docs citations

140  
times ranked

12183  
citing authors

#	ARTICLE	IF	CITATIONS
1	B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells. <i>Journal of Experimental Medicine</i> , 2001, 193, 839-846.	4.2	794
2	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1493.	3.8	775
3	Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2013, 73, 1733-1741.	0.4	678
4	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN- $\beta$ and IL-12. <i>Immunity</i> , 2018, 49, 1148-1161.e7.	6.6	639
5	<i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence. <i>Journal of Clinical Oncology</i> , 2014, 32, 2718-2726.	0.8	595
6	Highly prevalent TERT promoter mutations in aggressive thyroid cancers. <i>Endocrine-Related Cancer</i> , 2013, 20, 603-610.	1.6	500
7	Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009, 4, 49-70.	9.6	380
8	Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. <i>Head and Neck</i> , 2008, 30, 898-903.	0.9	353
9	Prospects of RNA interference therapy for cancer. <i>Gene Therapy</i> , 2006, 13, 464-477.	2.3	322
10	Human Papillomavirus-related Carcinomas of the Sinonasal Tract. <i>American Journal of Surgical Pathology</i> , 2013, 37, 185-192.	2.1	247
11	Targeting Human Papillomavirus Type 16 E7 to the Endosomal/Lysosomal Compartment Enhances the Antitumor Immunity of DNA Vaccines against Murine Human Papillomavirus Type 16 E7-Expressing Tumors. <i>Human Gene Therapy</i> , 1999, 10, 2727-2740.	1.4	204
12	Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. <i>Vaccine</i> , 2003, 21, 4036-4042.	1.7	164
13	Human Papillomavirus-related Carcinoma With Adenoid Cystic-like Features. <i>American Journal of Surgical Pathology</i> , 2013, 37, 836-844.	2.1	144
14	Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients With Oropharyngeal Cancer and Their Partners. <i>Journal of Clinical Oncology</i> , 2014, 32, 2408-2415.	0.8	139
15	Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. <i>Laryngoscope</i> , 2009, 119, 1542-1549.	1.1	129
16	Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. <i>Vaccine</i> , 2009, 27, 5450-5459.	1.7	114
17	Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. <i>Gene Therapy</i> , 2000, 7, 726-733.	2.3	110
18	Epigallocatechin-3-Gallate Enhances CD8+ T Cell-Mediated Antitumor Immunity Induced by DNA Vaccination. <i>Cancer Research</i> , 2007, 67, 802-811.	0.4	110

#	ARTICLE	IF	CITATIONS
19	Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. <i>Clinical Cancer Research</i> , 2002, 8, 1203-9.	3.2	105
20	Comparison of HPV DNA vaccines employing intracellular targeting strategies. <i>Gene Therapy</i> , 2004, 11, 1011-1018.	2.3	104
21	Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2013, 119, 3462-3471.	2.0	86
22	HPV Analysis in Distinguishing Second Primary Tumors From Lung Metastases in Patients With Head and Neck Squamous Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 142-148.	2.1	84
23	Activation of Akt as a Mechanism for Tumor Immune Evasion. <i>Molecular Therapy</i> , 2009, 17, 439-447.	3.7	80
24	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. <i>Cancer Research</i> , 2017, 77, 6365-6374.	0.4	77
25	A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 6011-6011.	0.8	65
26	Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. <i>British Journal of Cancer</i> , 2011, 104, 1896-1905.	2.9	63
27	Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 171-182.	2.0	63
28	PET/CT in the Management of Thyroid Cancers. <i>American Journal of Roentgenology</i> , 2014, 202, 1316-1329.	1.0	62
29	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 134-144.	0.4	61
30	In-situ tumor vaccination: Bringing the fight to the tumor. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1901-1909.	1.4	60
31	Application of the Hybrid Capture 2 assay to squamous cell carcinomas of the head and neck. <i>Cancer Cytopathology</i> , 2012, 120, 18-25.	1.4	59
32	The Impact of Molecular Testing on the Surgical Management of Patients with Thyroid Nodules. <i>Annals of Surgical Oncology</i> , 2014, 21, 1862-1869.	0.7	58
33	Epidemiology of Head and Neck Squamous Cell Cancer Among HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 603-610.	0.9	58
34	The relationship between chronic lymphocytic thyroiditis and central neck lymph node metastasis in North American patients with papillary thyroid carcinoma. <i>Surgery</i> , 2013, 154, 1272-1282.	1.0	57
35	High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. <i>Methods in Enzymology</i> , 2020, 635, 1-20.	0.4	57
36	Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 644-657.	3.2	49

#	ARTICLE	IF	CITATIONS
37	Biology of Human Papillomavirus Infection and Immune Therapy for HPV-Related Head and Neck Cancers. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 807-822.	0.5	48
38	Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas. <i>Oral Oncology</i> , 2013, 49, 244-248.	0.8	48
39	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. <i>Oral Oncology</i> , 2016, 61, 152-158.	0.8	48
40	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. <i>Nature Biotechnology</i> , 2020, 38, 420-425.	9.4	48
41	The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier. <i>Cancer Treatment and Research</i> , 2020, 180, 173-195.	0.2	48
42	Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. <i>Science Immunology</i> , 2021, 6, .	5.6	47
43	PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. <i>Endocrine Pathology</i> , 2018, 29, 59-67.	5.2	43
44	Functional and genomic analyses reveal therapeutic potential of targeting $\beta$ -catenin/CBP activity in head and neck cancer. <i>Genome Medicine</i> , 2018, 10, 54.	3.6	43
45	Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. <i>Gene Therapy</i> , 2011, 18, 304-312.	2.3	41
46	Characterization of the Methylation Patterns in Human Papillomavirus Type 16 Viral DNA in Head and Neck Cancers. <i>Cancer Prevention Research</i> , 2011, 4, 207-217.	0.7	41
47	Incidence of Malignancy in Thyroid Nodules Determined to be Follicular Lesions of Undetermined Significance on Fine-Needle Aspiration. <i>World Journal of Surgery</i> , 2012, 36, 69-74.	0.8	41
48	Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2011, 33, 1727-1734.	0.9	35
49	Vasopressin gene related products are markers of human breast cancer. <i>Breast Cancer Research and Treatment</i> , 1995, 34, 229-235.	1.1	34
50	Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. <i>Oral Oncology</i> , 2015, 51, 751-758.	0.8	34
51	Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)., 2019, 7, 96.		34
52	Reoperation for Recurrent/Persistent Well-Differentiated Thyroid Cancer. <i>Otolaryngologic Clinics of North America</i> , 2010, 43, 353-363.	0.5	32
53	Human papillomavirus status of head and neck cancer as determined in cytologic specimens using the hybrid-capture 2 assay. <i>Oral Oncology</i> , 2014, 50, 600-604.	0.8	32
54	The Molecular Genetics of Laryngeal Cancer. <i>Otolaryngologic Clinics of North America</i> , 2008, 41, 657-672.	0.5	31

#	ARTICLE	IF	CITATIONS
55	Central Compartment Neck Dissection for Thyroid Cancer. <i>Orl</i> , 2008, 70, 292-297.	0.6	30
56	A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response. <i>Journal of Biomedical Science</i> , 2004, 11, 493-499.	2.6	28
57	HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V. <i>Acta Oncol</i> , 2014, 53, 662-668.	0.8	27
58	Products of vasopressin gene expression in small-cell carcinoma of the lung. <i>British Journal of Cancer</i> , 1994, 69, 260-263.	2.9	26
59	Femtosecond laser treatment enhances DNA transfection efficiency in vivo. <i>Journal of Biomedical Science</i> , 2009, 16, 36.	2.6	26
60	Selective Versus Comprehensive Neck Dissection after Chemoradiation for Advanced Oropharyngeal Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2009, 141, 737-742.	1.1	26
61	Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. <i>Journal of Biomedical Science</i> , 2002, 9, 675-687.	2.6	25
62	Determining the extent of lateral neck dissection necessary to establish regional disease control and avoid reoperation after previous total thyroidectomy and radioactive iodine for papillary thyroid cancer. <i>Head and Neck</i> , 2012, 34, 1418-1421.	0.9	25
63	Tumor size and presence of calcifications on ultrasonography are preoperative predictors of lymph node metastases in patients with papillary thyroid cancer. <i>Journal of Surgical Oncology</i> , 2011, 104, 613-616.	0.8	22
64	Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. <i>Cancer</i> , 2018, 124, 84-94.	2.0	22
65	Ectopic Expression of X-Linked Lymphocyte-Regulated Protein pM1 Renders Tumor Cells Resistant to Antitumor Immunity. <i>Cancer Research</i> , 2010, 70, 3062-3070.	0.4	21
66	Sequential Cisplatin Therapy and Vaccination with HPV16 E6E7L2 Fusion Protein in Saponin Adjuvant GPI-0100 for the Treatment of a Model HPV16+ Cancer. <i>PLoS ONE</i> , 2015, 10, e116389.	1.1	20
67	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. <i>International Journal of Cancer</i> , 2016, 139, 510-517.	2.3	19
68	High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. <i>Molecular Cancer Research</i> , 2017, 15, 179-188.	1.5	19
69	Immunotherapy for head and neck cancer. <i>Journal of Biomedical Science</i> , 2008, 15, 275-289.	2.6	18
70	Combination of Viral Oncolysis and Tumor-Specific Immunity to Control Established Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4581-4588.	3.2	17
71	Aggressive recurrent respiratory papillomatosis in a neonate. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2008, 72, 917-920.	0.4	16
72	Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. <i>Laryngoscope</i> , 2010, 120, 504-510.	1.1	16

#	ARTICLE	IF	CITATIONS
73	Promoter methylation of leukemia inhibitory factor receptor gene in colorectal carcinoma. <i>International Journal of Oncology</i> , 2011, 39, 337-44.	1.4	16
74	Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. <i>Oncology</i> , 2013, 2, e24065.	2.1	15
75	Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications. <i>American Journal of Ophthalmology</i> , 2019, 200, 226-241.	1.7	15
76	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
77	Comparison of Acute Toxicities in Two Primary Chemoradiation Regimens in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 1980-1987.	0.7	14
78	Xenograft Model for Therapeutic Drug Testing in Recurrent Respiratory Papillomatosis. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2015, 124, 110-115.	0.6	14
79	Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling. <i>Clinical Cancer Research</i> , 2021, 27, 4781-4793.	3.2	14
80	Absence of TSG101 transcript abnormalities in human cancers. <i>Oncogene</i> , 1998, 16, 2815-2818.	2.6	12
81	Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity. <i>Laryngoscope</i> , 2017, 127, 1334-1338.	1.1	11
82	Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. <i>Journal of Biomedical Science</i> , 2002, 9, 675-87.	2.6	11
83	Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA. <i>Gene Therapy</i> , 2010, 17, 531-540.	2.3	10
84	A staged thyroidectomy approach for gastric bypass patients. <i>Laryngoscope</i> , 2015, 125, 1028-1030.	1.1	10
85	PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2020, 36, 444-450.	0.4	10
86	A phase II study of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal, and/or pulmonary involvement.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2502-2502.	0.8	10
87	Assignment of Two Human Autoantigen Genes—“Isoleucyl-tRNA Synthetase Locates to 9q21 and Lysyl-tRNA Synthetase Locates to 16q23—q24. <i>Genomics</i> , 1996, 36, 210-213.	1.3	9
88	High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. <i>American Journal of Ophthalmology</i> , 2020, 220, 128-139.	1.7	8
89	Concurrent sporadic parathyroid adenoma and carcinoma. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2006, 27, 346-348.	0.6	7
90	Central compartment lymph node dissection. <i>Operative Techniques in Otolaryngology - Head and Neck Surgery</i> , 2009, 20, 39-43.	0.1	7

#	ARTICLE	IF	CITATIONS
91	Mission impossible: How HPV-associated head and neck cancers escape a primed immune response. <i>Oral Oncology</i> , 2013, 49, 723-725.	0.8	7
92	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. <i>Oral Oncology</i> , 2018, 77, 92-97.	0.8	7
93	Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glands. <i>Cancer Reports</i> , 2022, 5, e1491.	0.6	7
94	Myeloid Cells Are Enriched in Tonsillar Crypts, Providing Insight into the Viral Tropism of Human Papillomavirus. <i>American Journal of Pathology</i> , 2021, 191, 1774-1786.	1.9	7
95	Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release. <i>Bioconjugate Chemistry</i> , 2022, 33, 1474-1484.	1.8	7
96	Delivery of chemotherapeutic agents using drug-loaded irradiated tumor cells to treat murine ovarian tumors. <i>Journal of Biomedical Science</i> , 2010, 17, 61.	2.6	6
97	Profile of Patients with Completion Thyroidectomy and Assessment of Their Suitability for Outpatient Surgery. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 145, 727-731.	1.1	6
98	Identification of the murine H-2Db and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 261-271.	2.0	6
99	New technology on the horizon: Fast analytical screening technique FNA (FAST-FNA) enables rapid, multiplex biomarker analysis in head and neck cancers. <i>Cancer Cytopathology</i> , 2020, 128, 782-791.	1.4	6
100	IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6053-6053.	0.8	6
101	A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6082-6082.	0.8	6
102	Laryngeal Muscle Surface Receptors Identified using Random Phage Library. <i>Laryngoscope</i> , 2005, 115, 1930-1937.	1.1	5
103	Hyperfractionated Radiotherapy with Concurrent Cisplatin/5-Fluorouracil for Locoregional Advanced Head and Neck Cancer: Analysis of 105 Consecutive Patients. <i>International Journal of Otolaryngology</i> , 2012, 2012, 1-10.	1.0	5
104	Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 2433-2443.	0.9	5
105	Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1273-1286.	2.0	5
106	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Journal of Translational Medicine</i> , 2019, 17, 429.	1.8	5
107	Multiplexed single-cell analysis of FNA allows accurate diagnosis of salivary gland tumors. <i>Cancer Cytopathology</i> , 2022, 130, 581-594.	1.4	5
108	Localization of Two Human Autoantigen Genes by PCR Screening and in Situ Hybridization: Glycyl-tRNA Synthetase Locates to 7p15 and Alanyl-tRNA Synthetase Locates to 16q22. <i>Genomics</i> , 1995, 30, 131-132.	1.3	4



#	ARTICLE	IF	CITATIONS
109	Leiomyosarcoma of the Auricle. <i>Otolaryngology - Head and Neck Surgery</i> , 2003, 128, 442-444.	1.1	4
110	Successful Treatment of an Aggressive Tracheal Malignancy With Immunotherapy. <i>Annals of Thoracic Surgery</i> , 2017, 103, e123-e125.	0.7	4
111	Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses.. <i>Journal of Clinical Oncology</i> , 2013, 31, CRA6031-CRA6031.	0.8	4
112	A retrospective cohort study of PD-L1 expression in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SUPREME-HN).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6040-6040.	0.8	4
113	A DNA Vaccine Co-Expressing Antigen and an Anti-Apoptotic Molecule Further Enhances the Antigen-Specific CD8&plus; T-Cell Immune Response. <i>Journal of Biomedical Science</i> , 2004, 11, 493-499.	2.6	3
114	Differential expression of epidermal growth factor receptor in juvenile and adult-onset recurrent respiratory papillomatosis. <i>Histopathology</i> , 2010, 57, 768-770.	1.6	3
115	Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit. , 2020, 8, e000112.		3
116	Pulmonary manifestations of chronic HPV infection in patients with recurrent respiratory papillomatosis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 997-1008.	5.2	3
117	Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses.. <i>Journal of Clinical Oncology</i> , 2013, 31, CRA6031-CRA6031.	0.8	2
118	A rabbit model to investigate temporomandibular joint osteochondral regeneration. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2022, 134, 20-27.	0.2	2
119	The Diagnostic Accuracy of Computed Tomography in Pediatric Chronic Rhinosinusitis. <i>Pediatrics</i> , 2005, 116, 551-552.	1.0	1
120	HPV-Associated Head and Neck Cancers. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, xi-xii.	0.5	1
121	Oncopolicy in high-income countries can make a difference in HPV-related Head and Neck Cancer. <i>Journal of Cancer Policy</i> , 2013, 1, e49-e51.	0.6	1
122	Programmed cell death ligand 1 as a biomarker in head and neck cancer. <i>Cancer Cytopathology</i> , 2017, 125, 529-533.	1.4	1
123	Peripheral Circulating CD45RA <sup>+</sup> FOXP3 <sup>hi</sup> T Regulatory (TReg) II Cells Provide a Window into the Activity of Intratumoral TReg Cells. <i>Trends in Cancer</i> , 2020, 6, 3-6.	3.8	1
124	Patient-reported outcomes (PROs) from a phase II trial of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal and/or pulmonary involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6080-6080.	0.8	1
125	ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6052-6052.	0.8	1
126	PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5506-5506.	0.8	1



#	ARTICLE	IF	CITATIONS
127	The Role of Vaccines for HPV-Related Head and Neck Cancers. <i>Head and Neck Cancer Clinics</i> , 2015, , 99-110.	0.0	1
128	354â€¦A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer. , 2020, , .		1
129	A phase II study of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal, and/or pulmonary involvement.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2590-2590.	0.8	1
130	A retropharyngeal pseudoabscess in a patient with paroxysmal nocturnal hemoglobinuria. <i>Otolaryngology - Head and Neck Surgery</i> , 2007, 137, 684-686.	1.1	0
131	Preface. <i>Otolaryngologic Clinics of North America</i> , 2010, 43, xiii-xiv.	0.5	0
132	Checkpoint cluster: biomarkers of response. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 501-508.	1.1	0
133	Oncoviruses. , 2018, , 90-106.		0
134	A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3119-TPS3119.	0.8	0
135	Expression of tumor biomarkers in HIV-infected patients with head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6086-6086.	0.8	0
136	Intact APM and PD-1:PD-L1 pathway upregulation in HIV-infected head and neck cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6058-6058.	0.8	0
137	Abstract P056: Rapid serial immunoprofiling of the tumor immune microenvironment by fine needle sampling. , 2022, , .		0
138	FAST-FNA molecular diagnostic assay facilitates rapid diagnosis and ntrk biomarker testing of salivary gland tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18089-e18089.	0.8	0